SubHero Banner

Exkivity® (mobocertinib) – Drug withdrawal

October 2, 2023 - Takeda announced the voluntary withdrawal of Exkivity (mobocertinib), for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

Download PDF